Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype. - Université de Lille Accéder directement au contenu
Article Dans Une Revue Bone Marrow Transplantation Année : 2023

Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype.

Résumé

Allogeneic hematopoietic cell transplantation (allo-HCT) remains the best consolidation strategy for acute myeloid leukemia (AML) with complex karyotype (CK). However, CK is a heterogenous and highly diverse entity. Numerical abnormalities have been associated with a controversial prognosis and AML with only multiple numerical abnormalities known as pure hyperdiploid karyotype (HDK) may have a distinct prognosis after allo-HCT compared to non-pure HDK CK AML. A total of 236 patients were identified within the EBMT registry as having HDK comprising 95 pure (pHDK) and 141 with other cytogenetic abnormalities (HDK+). The 2-year probability of leukemia-free survival (LFS) was 50% for pHDK and 31% for HDK+ (p = 0.003). The 2-year probability of overall survival (OS) was 57% for pHDK and 36% for HDK+ (p = 0.007). The 2-year cumulative incidence of relapse (RI) was 22% for pHDK and 44% for HDK+ (p = 0.001). The 2-year probability of graft-versus-host disease (GvHD)-free and relapse-free survival (GRFS) was 36% for pHDK and 21% for HDK+ (p = 0.01). On multivariate analysis, pHDK remained associated with significantly better LFS, OS and GRFS and lower RI (all p-values <0.004). pHDK AML constitutes probably a distinct cytogenetic entity from HDK+ or other non-hyperdiploid CK AML with better outcomes after allo-HCT.

Dates et versions

hal-04513061 , version 1 (20-03-2024)

Identifiants

Citer

Xavier Poire, Myriam Labopin, Emmanuelle Polge, Arnold Ganser, Gérard Socié, et al.. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype.. Bone Marrow Transplantation, 2023, Bone Marrow Transplantation, ⟨10.1038/s41409-023-02167-1⟩. ⟨hal-04513061⟩
1 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More